# A Study of Lasmiditan in Healthy Chinese Participants

> **NCT04081324** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lasmiditan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04081324
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2020-06-15
- **Final completion:** 2020-06-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04081324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04081324, "A Study of Lasmiditan in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04081324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*